Advertisement

Sex and Gender-Related Issues in Heart Failure

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Cardiology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Levinsson A.
        • Dubé M.P.
        • Tardif J.C.
        • et al.
        Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines.
        ESC Heart Fail. 2018; https://doi.org/10.1002/ehf2.12307
        • Benjamin E.J.
        • Muntner P.
        • Alonso A.
        • et al.
        Heart disease and stroke statistics-2019 update: a report from the American Heart Association.
        Circulation. 2019; 139: e56-e66https://doi.org/10.1161/CIR.0000000000000659
        • Roger V.L.
        Epidemiology of heart failure.
        Circ Res. 2013; 113: 646-659
        • Levy D.
        • Kenchaiah S.
        • Larson M.G.
        • et al.
        Long-term trends in the incidence of and survival with heart failure.
        N Engl J Med. 2002; 347: 1397-1402
        • Magnussen C.
        • Niiranen T.J.
        • Ojeda F.M.
        • et al.
        Sex-specific epidemiology of heart failure risk and mortality in Europe.
        JACC Hear Fail. 2019; 7: 204-213
        • Roger V.L.
        • Weston S.A.
        • Redfield M.M.
        • et al.
        Trends in heart failure incidence and survival in a community-based population.
        JAMA. 2004; 292: 344
        • Barker W.H.
        • Mullooly J.P.
        • Getchell W.
        Changing incidence and survival for heart failure in a well-defined older population, 1970–1974 and 1990–1994.
        Circulation. 2006; 113: 799-805
        • Marra A.M.
        • Salzano A.
        • Arcopinto M.
        • et al.
        The impact of gender in cardiovascular medicine: lessons from the gender/sex-issue in heart failure.
        Monaldi Arch Chest Dis. 2018; 88: 988
        • Daubert M.A.
        • Douglas P.S.
        Primary prevention of heart failure in women.
        JACC Hear Fail. 2019; 7: 181-191
        • Meyer S.
        • Van Der Meer P.
        • Van Deursen V.M.
        • et al.
        Neurohormonal and clinical sex differences in heart failure.
        Eur Heart J. 2013; 34: 2538-2547
        • Dunlay S.M.
        • Roger V.L.
        • Redfield M.M.
        Epidemiology of heart failure with preserved ejection fraction.
        Nat Rev Cardiol. 2017; 14: 591-602
        • Pandey A.
        • Omar W.
        • Ayers C.
        • et al.
        Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.
        Circulation. 2018; 137: 1814-1823
        • Ho J.E.
        • Enserro D.
        • Brouwers F.P.
        • et al.
        Predicting heart failure with preserved and reduced ejection fraction.
        Circ Heart Fail. 2016; 9
        • Levy D.
        • Larson M.G.
        • Vasan R.S.
        • et al.
        The progression from hypertension to congestive heart failure.
        JAMA. 1996; 275: 1557-1562
        • Kannel W.B.
        • Hjortland M.
        • Castelli W.P.
        Role of diabetes in congestive heart failure: the Framingham study.
        Am J Cardiol. 1974; 34: 29-34
        • Lundberg G.
        • Walsh M.N.
        • Mehta L.S.
        Sex-specific differences in risk factors for development of heart failure in women.
        Heart Fail Clin. 2019; 15: 1-8
        • Lenzen M.J.
        • Rosengren A.
        • op Reimer W.J.M.S.
        • et al.
        Management of patients with heart failure in clinical practice: differences between men and women.
        Heart. 2008; 94: e10
        • Shafazand M.
        • Schaufelberger M.
        • Lappas G.
        • et al.
        Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry.
        Eur Heart J. 2008; 30: 671-678
        • Wenger N.K.
        • Arnold A.
        • Bairey Merz C.N.
        • et al.
        Hypertension across a woman’s life cycle.
        J Am Coll Cardiol. 2018; 71: 1797-1813
        • Albrektsen G.
        • Heuch I.
        • Løchen M.-L.
        • et al.
        Lifelong gender gap in risk of incident myocardial infarction.
        JAMA Intern Med. 2016; 176: 1673
        • Frazier C.G.
        • Alexander K.P.
        • Newby L.K.
        • et al.
        Associations of gender and etiology with outcomes in heart failure with systolic dysfunction.
        J Am Coll Cardiol. 2007; 49: 1450-1458
        • Simon T.
        • Mary-Krause M.
        • Funck-Brentano C.
        • et al.
        Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II).
        Circulation. 2001; 103: 375-380
        • Uijl A.
        • Koudstaal S.
        • Direk K.
        • et al.
        Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records.
        Eur J Heart Fail. 2019; https://doi.org/10.1002/ejhf.1350
        • Franke J.
        • Lindmark A.
        • Hochadel M.
        • et al.
        Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the Heart Failure Survival Score.
        Clin Res Cardiol. 2015; 104: 334-341
        • Raparelli V.
        • Proietti M.
        • Lenzi A.
        • et al.
        Sex and gender differences in ischemic heart disease: endocrine vascular disease approach (EVA) study design.
        J Cardiovasc Transl Res. 2018; https://doi.org/10.1007/s12265-018-9846-5
        • He J.
        • Ogden L.G.
        • Bazzano L.A.
        • et al.
        Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study.
        Arch Intern Med. 2001; 161: 996-1002
        • Kenchaiah S.
        • Evans J.C.
        • Levy D.
        • et al.
        Obesity and the risk of heart failure.
        N Engl J Med. 2002; 347: 305-313
        • Marzona I.
        • Proietti M.
        • Farcomeni A.
        • et al.
        Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: a systematic review and meta-analysis of 993,600 patients.
        Int J Cardiol. 2018; 269: 182-191
        • Santhanakrishnan R.
        • Wang N.
        • Larson M.G.
        • et al.
        Atrial fibrillation begets heart failure and vice versa.
        Circulation. 2016; 133: 484-492
        • Benjamin E.J.
        • Levy D.
        • Vaziri S.M.
        • et al.
        Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.
        JAMA. 1994; 271: 840-844
        • Hopper I.
        • Kotecha D.
        • Chin K.L.
        • et al.
        Comorbidities in heart failure: are there gender differences?.
        Curr Heart Fail Rep. 2016; 13: 1-12
        • Chamberlain A.M.
        • St. Sauver J.L.
        • Gerber Y.
        • et al.
        Multimorbidity in heart failure: a community perspective.
        Am J Med. 2015; 128: 38-45
        • Hsich E.M.
        • Piña I.L.
        Heart failure in women. A need for prospective data.
        J Am Coll Cardiol. 2009; https://doi.org/10.1016/j.jacc.2009.02.066
        • Dickstein K.
        • Solomon S.D.
        • Dewan P.
        • et al.
        Differential impact of heart failure with reduced ejection fraction on men and women.
        J Am Coll Cardiol. 2019; https://doi.org/10.1016/j.jacc.2018.09.081
        • Garavaglia G.E.
        • Messerli F.H.
        • Schmieder R.E.
        • et al.
        Sex differences in cardiac adaptation to essential hypertension.
        Eur Heart J. 1989; https://doi.org/10.1093/oxfordjournals.eurheartj.a059434
        • Romiti G.F.
        • Cangemi R.
        • Toriello F.
        • et al.
        Sex-specific cut-offs for high-sensitivity cardiac troponin: is less more?.
        Cardiovasc Ther. 2019; 2019: 1-12
        • Hamada M.
        • Shigematsu Y.
        • Takezaki M.
        • et al.
        Plasma levels of atrial and brain natriuretic peptides in apparently healthy subjects: effects of sex, age, and hemoglobin concentration.
        Int J Cardiol. 2017; 228: 599-604
        • Slagman A.
        • Searle J.
        • Vollert J.O.
        • et al.
        Sex differences of troponin test performance in chest pain patients.
        Int J Cardiol. 2015; 187: 246-251
        • Heiat A.
        • Gross C.P.
        • Krumholz H.M.
        Representation of the elderly, women, and minorities in heart failure clinical trials.
        Arch Intern Med. 2002; 162: 1682-1688
        • Tahhan A.S.
        • Vaduganathan M.
        • Greene S.J.
        • et al.
        Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review.
        JAMA Cardiol. 2018; 3: 1011-1019
        • Taylor A.L.
        • Ziesche S.
        • Yancy C.
        • et al.
        Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
        N Engl J Med. 2004; 351: 2049-2057
        • McMurray J.J.V.
        • Krum H.
        • Abraham W.T.
        • et al.
        Aliskiren, enalapril, or aliskiren and enalapril in heart failure.
        N Engl J Med. 2016; 374: 1521-1532
        • Fox K.
        • Ford I.
        • Steg P.G.
        • et al.
        Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2008; 372: 807-816
        • Eichhorn E.J.
        • Domanski M.J.
        • Krause-Steinrauf H.
        • et al.
        • Beta-Blocker Evaluation of Survival Trial Investigators
        A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.
        N Engl J Med. 2001; 344: 1659-1667
        • Cleland J.G.F.
        • Daubert J.-C.
        • Erdmann E.
        • et al.
        The effect of cardiac resynchronization on morbidity and mortality in heart failure.
        N Engl J Med. 2005; 352: 1539-1549
        • Pfeffer M.A.
        • Swedberg K.
        • Granger C.B.
        • et al.
        Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
        Lancet. 2003; 362: 759-766
        • CIBIS-II Investigators and Committees
        The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
        Lancet. 1999; 353: 9-13
        • Bristow M.R.
        • Saxon L.A.
        • Boehmer J.
        • et al.
        Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
        N Engl J Med. 2004; 350: 2140-2150
        • Poole-Wilson P.A.
        • Swedberg K.
        • Cleland J.G.
        • et al.
        Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
        Lancet. 2003; 362: 7-13
        • CONSENSUS Trial Study Group
        Effects of enalapril on mortality in severe congestive heart failure.
        N Engl J Med. 1987; 316: 1429-1435
        • Packer M.
        • Coats A.J.
        • Fowler M.B.
        • et al.
        Effect of carvedilol on survival in severe chronic heart failure.
        N Engl J Med. 2001; 344: 1651-1658
        • Kjekshus J.
        • Apetrei E.
        • Barrios V.
        • et al.
        Rosuvastatin in older patients with systolic heart failure.
        N Engl J Med. 2007; 357: 2248-2261
        • Digitalis Investigation Group
        The effect of digoxin on mortality and morbidity in patients with heart failure.
        N Engl J Med. 1997; 336: 525-533
        • Pitt B.
        • Segal R.
        • Martinez F.A.
        • et al.
        Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).
        Lancet. 1997; 349: 747-752
        • Zannad F.
        • McMurray J.J.V.
        • Krum H.
        • et al.
        Eplerenone in patients with systolic heart failure and mild symptoms.
        N Engl J Med. 2011; 364: 11-21
        • Pitt B.
        • Remme W.
        • Zannad F.
        • et al.
        Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
        N Engl J Med. 2003; 348: 1309-1321
        • Massie B.M.
        • Carson P.E.
        • McMurray J.J.
        • et al.
        Irbesartan in patients with heart failure and preserved ejection fraction.
        N Engl J Med. 2008; 359: 2456-2467
        • Moss A.J.
        • Hall W.J.
        • Cannom D.S.
        • et al.
        Cardiac-resynchronization therapy for the prevention of heart-failure events.
        N Engl J Med. 2009; 361: 1329-1338
        • Moss A.J.
        • Zareba W.
        • Hall W.J.
        • et al.
        Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
        N Engl J Med. 2002; 346: 877-883
        • MERIT-HF Study Group
        Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).
        Lancet. 1999; 353: 2001-2007
        • McMurray J.J.V.
        • Packer M.
        • Desai A.S.
        • et al.
        Angiotensin–neprilysin inhibition versus enalapril in heart failure.
        N Engl J Med. 2014; 371: 993-1004
        • Solomon S.D.
        • Zile M.
        • Pieske B.
        • et al.
        The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
        Lancet. 2012; 380: 1387-1395
        • Velazquez E.J.
        • Morrow D.A.
        • DeVore A.D.
        • et al.
        Angiotensin–neprilysin inhibition in acute decompensated heart failure.
        N Engl J Med. 2019; 380: 539-548
        • Pitt B.
        • Zannad F.
        • Remme W.J.
        • et al.
        The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
        N Engl J Med. 1999; 341: 709-717
        • Flather M.D.
        • Shibata M.C.
        • Coats A.J.S.
        • et al.
        Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
        Eur Heart J. 2005; 26: 215-225
        • Swedberg K.
        • Komajda M.
        • Böhm M.
        • et al.
        Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
        Lancet. 2010; 376: 875-885
        • Investigators T.S.
        Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.
        N Engl J Med. 1992; 327: 685-691
        • Investigators T.S.
        Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
        N Engl J Med. 1991; 325: 293-302
        • Pitt B.
        • Pfeffer M.A.
        • Assmann S.F.
        • et al.
        Spironolactone for heart failure with preserved ejection fraction.
        N Engl J Med. 2014; 370: 1383-1392
        • Packer M.
        • Bristow M.R.
        • Cohn J.N.
        • et al.
        The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
        N Engl J Med. 1996; 334: 1349-1355
        • Cohn J.N.
        • Tognoni G.
        A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
        N Engl J Med. 2001; 345: 1667-1675
        • Cohn J.N.
        • Archibald D.G.
        • Ziesche S.
        • et al.
        Effect of vasodilator therapy on mortality in chronic congestive heart failure.
        N Engl J Med. 1986; 314: 1547-1552
        • Cohn J.N.
        • Johnson G.
        • Ziesche S.
        • et al.
        A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure.
        N Engl J Med. 1991; 325: 303-310
        • Shin J.J.
        • Hamad E.
        • Murthy S.
        • et al.
        Heart failure in women.
        Clin Cardiol. 2012; 35: 172-177
        • Saitta A.
        • Altavilla D.
        • Cucinotta D.
        • et al.
        Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women.
        Arterioscler Thromb Vasc Biol. 2001; 21: 1512-1519
        • Tamargo J.
        • Rosano G.
        • Walther T.
        • et al.
        Gender differences in the effects of cardiovascular drugs.
        Eur Heart J Cardiovasc Pharmacother. 2017; 3: 163-182
        • Cangemi R.
        • Romiti G.F.
        • Campolongo G.
        • et al.
        Gender related differences in treatment and response to statins in primary and secondary cardiovascular prevention: the never-ending debate.
        Pharmacol Res. 2017; 117: 148-155
        • Raparelli V.
        • Proietti M.
        • Romiti G.F.
        • et al.
        The sex-specific detrimental effect of diabetes and gender-related factors on pre-admission medication adherence among patients hospitalized for ischemic heart disease: insights from EVA study.
        Front Endocrinol (Lausanne). 2019; 10https://doi.org/10.3389/fendo.2019.00107
        • D’Agostino R.B.S.
        • Grundy S.
        • Sullivan L.M.
        • et al.
        Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.
        JAMA. 2001; 286: 180-187
        • Rathore S.S.
        • Wang Y.
        • Krumholz H.M.
        Sex-based differences in the effect of digoxin for the treatment of heart failure.
        N Engl J Med. 2002; 347: 1403-1411
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinic.
        Circulation. 2016; 134: e282-e293
        • Konstam M.A.
        • Neaton J.D.
        • Dickstein K.
        • et al.
        Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
        Lancet. 2009; 374: 1840-1848
        • Adams K.F.J.
        • Patterson J.H.
        • Gattis W.A.
        • et al.
        Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis.
        J Am Coll Cardiol. 2005; 46: 497-504
        • Rathore S.S.
        • Curtis J.P.
        • Wang Y.
        • et al.
        Association of serum digoxin concentration and outcomes in patients with heart failure.
        JAMA. 2003; 289: 871-878
        • Merrill M.
        • Sweitzer N.K.
        • Lindenfeld J.A.
        • et al.
        Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial.
        JACC Hear Fail. 2019; https://doi.org/10.1016/j.jchf.2019.01.003
        • Santangeli P.
        • Pelargonio G.
        • Dello Russo A.
        • et al.
        Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis.
        Hear Rhythm. 2010; 7: 876-882
        • Barsheshet A.
        • Brenyo A.
        • Goldenberg I.
        • et al.
        Sex-related differences in patients’ responses to heart failure therapy.
        Nat Rev Cardiol. 2012; https://doi.org/10.1038/nrcardio.2012.10
        • Vaduganathan M.
        • Tahhan A.S.
        • Alrohaibani A.
        • et al.
        Do women and men respond similarly to therapies in contemporary heart failure clinical trials?.
        JACC Hear Fail. 2019; https://doi.org/10.1016/j.jchf.2018.12.016
        • Clayton J.A.
        • Tannenbaum C.
        Reporting sex, gender, or both in clinical research?.
        JAMA. 2016; 316: 1863-1864
        • Legato M.J.
        • Johnson P.A.
        • Manson J.E.
        Consideration of sex differences in medicine to improve health care and patient outcomes.
        JAMA. 2016; 316: 1865-1866
        • Canadian Institutes of Health Research
        What is gender? What is sex?.
        (Available at:) (Accessed September 26, 2018)
        • Johnson J.L.
        • Greaves L.
        • Repta R.
        Better science with sex and gender: a primer for health research.
        Women’s Health Research Network, Vancouver (Canada)2007
        • Georgiopoulou V.V.
        • Velayati A.
        • Burkman G.
        • et al.
        Comorbidities, sociodemographic factors, and hospitalizations in outpatients with heart failure and preserved ejection fraction.
        Am J Cardiol. 2018; https://doi.org/10.1016/j.amjcard.2018.01.040
        • Schockmel M.
        • Agrinier N.
        • Jourdain P.
        • et al.
        Socioeconomic factors and mortality in diastolic heart failure.
        Eur J Clin Invest. 2014; 44: 372-383
        • Watkins T.
        • Mansi M.
        • Thompson J.
        • et al.
        Effect of marital status on clinical outcome of heart failure.
        J Investig Med. 2013; 61: 835-841https://doi.org/10.2310/JIM.0b013e31828c823e
        • Braunwald E.
        Biomarkers in heart failure.
        N Engl J Med. 2008; 358: 2148-2159
        • Neuhold S.
        • Huelsmann M.
        • Strunk G.
        • et al.
        Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy.
        Clin Chem. 2010; 56: 121-126
        • Rørth R.
        • Fosbøl E.L.
        • Mogensen U.M.
        • et al.
        Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure.
        Eur J Heart Fail. 2018; https://doi.org/10.1002/ejhf.1046
        • Capdevila C.
        • Bilal U.
        • Farre N.
        • et al.
        Individual income, mortality and healthcare resource use in patients with chronic heart failure living in a universal healthcare system: a population-based study in Catalonia, Spain.
        Int J Cardiol. 2018; https://doi.org/10.1016/j.ijcard.2018.10.099
        • Hawkins N.M.
        • Scholes S.
        • Bajekal M.
        • et al.
        Community care in England.
        Circulation. 2012; 126: 1050-1057
        • Pauws S.C.
        • Sokoreli I.
        • Clark A.L.
        • et al.
        Added value of frailty and social support in predicting risk of 30-day unplanned re-admission or death for patients with heart failure: an analysis from OPERA-HF.
        Int J Cardiol. 2018; https://doi.org/10.1016/j.ijcard.2018.12.030
        • Makowska A.
        • Rydlewska A.
        • Krakowiak B.
        • et al.
        Psychological gender of men with systolic heart failure: a neglected strategy to cope with the disease?.
        Am J Mens Health. 2014; 8: 249-257https://doi.org/10.1177/1557988313508429